Tuberculosis Vaccine Treatment Market Research Report - Global Forecast till 2027

Tuberculosis Vaccine Treatment Market Research Report, Type Of Test (Tuberculin Skin Test (TST), TB Blood Tests, Igras), Type Of TB Vaccine (Immunotherapeutic Vaccines, Booster Vaccines), End Users (Hospitals, Private Clinics) - Global Forecast Till 2027

ID: MRFR/Pharma/1152-HCR | February 2021 | Region: Global | 100 pages         

Tuberculosis Vaccine Treatment Market Speak to Analyst Request a Free Sample

Tuberculosis Vaccine Treatment Market Scenario:


Tuberculosis (TB) is an infectious disease which is caused by the bacteria called Mycobacterium tuberculosis (MTB). Tuberculosis mainly affects lungs, but can also affect other parts of the body. Typical signs of tuberculosis includes chronic or persistent cough and sputum production. When TB is at an advanced stage the sputum will contain blood and other symptoms include lack of appetite, weight loss, fever, and night sweats.


 The vaccines trigger a potent immune response against infectious diseases; tuberculosis (TB) vaccines prevent infection with tuberculosis. Robert Koch was first to propose immunotherapy as a defense mechanism against TB. Currently, the only effective tuberculosis vaccine is BCG (Bacilli Calmette-Guerin).


Increasing awareness about vaccination, growing government funding for vaccination programs and increasing prevalence of infectious diseases drive the growth of the Tuberculosis Vaccine Treatment Market. Furthermore, improving healthcare infrastructure and emphasis on prevention of diseases drive the growth of Tuberculosis Vaccine Treatment Market.


According to Centers for disease control and prevention, One third of the world’s population is infected with TB. In 2016, 10.4 million people around the world became sick with TB disease. There were 1.7 million TB-related deaths worldwide. A total of 9,272 TB cases (a rate of 2.9 cases per 100,000 persons) were reported in the United States in 2016.


However, on the other hand, side effects occurring from the vaccinations and the government approval time for the vaccine are the major factors that may hinder the growth of the Tuberculosis Vaccine Treatment Market.


The tuberculosis vaccine treatment market is expected to grow at a CAGR of 8.7% during the forecast period 2017-2023.  


Intended Audience



  • Research and Development (R&D) Companies

  • Government and Independent Research Laboratories

  • Tuberculosis Vaccines Manufacturers

  • Tuberculosis Vaccines Suppliers

  • Government and Independent Regulatory Authorities

  • Academic Medical Institutes and Universities


Figure 1- Tuberculosis vaccine treatment market, by type of TB test tuberculosis vaccine treatment market


    Annual reports, press release, white paper, company presentation 


Segmentation


Tuberculosis vaccine treatment market is segmented on the basis of types of test, type of TB vaccines, and end users.


On the basis of type of test, it is segmented into tuberculin skin test (TST), TB blood tests, IGRAs (interferon-gamma release assays), and others.


On the basis of type of Tb vaccines, it is segmented into immunotherapeutic vaccines, booster vaccines, and others.


And on the basis of end users, it is segmented into hospitals, private clinics, research institutes, and others.  


Regional Analysis 

On the regional basis, the tuberculosis vaccine treatment market is segmented into America, Europe, Asia Pacific and the Middle East & Africa.


America holds the largest market share of TB vaccines due to the major market players are concentrated and its emphasis on vaccination against TB.


Europe accounts for the second largest market for TB vaccines; this is due to increase in research and development activities by research institutions and pharmaceutical companies. According to UK TB statistics reports, in 2016 there were 5,664 TB cases 39% of cases were in diagnosed in London and 3.8% of people with TB were also living with HIV.


Asia Pacific is expected to be the fastest growing market for Tuberculosis vaccines market over the forecast period. India and China are expected to be emerging and fastest growing countries in this regional market.


According to WHO, India accounts with the highest burden of TB. In 2015, an estimated incidence of 2.84 million cases of TB in India.


On the other hand, The Middle East and Africa holds least market share due to limited screening, ignorance of diseases, and poor access to treatment.


Key Players 

Merck & Co., Inc.(US), Sanofi Pasteur SA (France), Serum Institute of India Pvt. Ltd. (India), GlaxoSmithKline plc (UK), IDT Biologics GmbH, GreenSignal Bio Pharma Limited (India), Taj Pharmaceuticals Limited (India), Bavarian Nordic(US), Solvay(US), Informa plc.(US) and others. 


Market Assessment


Tuberculosis Vaccine Treatment Market-


Annual reports, World Health Organization (WHO), white paper, company presentation



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Tuberculosis vaccine treatment market can exhibit a CAGR of 8.7% from 2017 to 2023.

Government funding for vaccination programs, awareness of TB, and efforts for prevention of the spread of these diseases are major drivers of the global tuberculosis vaccine treatment market..

Side-effects of the vaccines and long waiting times for approval of vaccines from government regulatory agencies can restrain the global tuberculosis vaccine treatment market.

APAC can display a robust growth rate in the global tuberculosis vaccine treatment market till 2023 owing to high cases of TB in Indi

GlaxoSmithKline plc, Informa plc., Serum Institute of India Pvt. Ltd., Solvay, IDT Biologics GmbH, Taj Pharmaceuticals Limited, Merck & Co., Inc., Sanofi Pasteur SA, Bavarian Nordic, and GreenSignal Bio Pharma Limited are key players of the global tuberculosis vaccine treatment market.